FarmavitaR+

regulatory affairs network

  • Increase font size
  • Default font size
  • Decrease font size

News-Bulgarian Drug Agency

E-mail Print PDF

clock.jpgBulgaria Will   be a reference Member State

BDA triggers a timetable definition in order to prepare slots for assessment of the marketing authorization applications in MRP and DCP procedures for which Bulgaria is to be a reference Member State under Art. 76 (1) and (3) of LMPHM.

Prior to submission of the application forms under Art. 74 or 75 of LMPHM, a certain preliminary information should be provided, aiming an initial evaluation of the applicants. Template for the data necessary is available in the section "Marketing Authorization of Medicinal Products/Announcement".

Documents specified are to be applied by the end of February 2009. Following their assessment the applications under Art. 74 or 75 of LMPHM will be admitted.

 
Banner


Login With Facebook

Active Groups

{captcha}